Free Trial
NASDAQ:CARM

Carisma Therapeutics (CARM) Stock Price, News & Analysis

$1.35
+0.09 (+7.14%)
(As of 05/24/2024 ET)
Today's Range
$1.26
$1.36
50-Day Range
$1.26
$2.54
52-Week Range
$1.24
$9.77
Volume
190,603 shs
Average Volume
160,889 shs
Market Capitalization
$56.08 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$8.60

Carisma Therapeutics MarketRank™ Stock Analysis

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
537.0% Upside
$8.60 Price Target
Short Interest
Bearish
9.41% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
0.83mentions of Carisma Therapeutics in the last 14 days
Based on 3 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
Growing
From ($1.72) to ($1.53) Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

1.51 out of 5 stars

Medical Sector

703rd out of 917 stocks

Pharmaceutical Preparations Industry

319th out of 410 stocks

CARM stock logo

About Carisma Therapeutics Stock (NASDAQ:CARM)

Carisma Therapeutics, Inc., a clinical-stage cell therapy company, focuses on discovering and developing immunotherapies to treat cancer and other serious diseases in the United States. The company's ex vivo CAR-M cell therapies include CT-0508, a CAR-macrophage, which is in Phase 1 clinical trial to treat solid tumors; CT-0525, a CAR-monocyte that is in Phase 1 clinical trial to treat solid tumors; and CT-1119, a mesothelin-targeted CAR-Monocyte that is in pre-clinical stage to treat patients with advanced mesothelin-positive solid tumors, including lung cancer, mesothelioma, pancreatic cancer, ovarian cancer, and others. It is also developing in vivo CAR-M cell therapies in collaboration with Moderna Therapeutics to address multiple cancer targets; and multiple assets for the potential treatment of diseases beyond oncology, including fibrosis and other immunologic and inflammatory diseases. The company was formerly known as CARMA Therapeutics Inc. and changed its name to Carisma Therapeutics, Inc. in May 2017. The company was founded in 2016 and is headquartered in Philadelphia, Pennsylvania.

CARM Stock Price History

CARM Stock News Headlines

The Analyst Verdict: CARISMA Therapeutics In The Eyes Of 4 Experts
See More Headlines
Receive CARM Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Carisma Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
4/01/2024
Today
5/25/2024
Next Earnings (Estimated)
8/08/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
N/A
Current Symbol
NASDAQ:CARM
Web
N/A
Employees
107
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$8.60
High Stock Price Target
$12.00
Low Stock Price Target
$6.00
Potential Upside/Downside
+537.0%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
5 Analysts

Profitability

Net Income
$-86,880,000.00
Net Margins
-538.81%
Pretax Margin
-539.53%

Debt

Sales & Book Value

Annual Sales
$14.92 million
Book Value
$0.26 per share

Miscellaneous

Free Float
34,481,000
Market Cap
$56.08 million
Optionable
No Data
Beta
1.00
These 7 Stocks Will Be Magnificent in 2024 Cover

With average gains of 150% since the start of 2023, now is the time to give these stocks a look and pump up your 2024 portfolio.

Get This Free Report

Key Executives

  • Mr. Steven Kelly (Age 59)
    President, CEO & Director
    Comp: $786.91k
  • Mr. Michael Klichinsky Ph.D. (Age 34)
    Pharm.D., PharmD, Co-Founder & Chief Scientific Officer
    Comp: $525.43k
  • Mr. Richard S. Morris CPA (Age 50)
    CFO, Chief Compliance Officer, Treasurer, Prin. Financial Off. & Prin. Acc. Off.
    Comp: $584.85k
  • Dr. Saar Gill M.D.
    Ph.D., Co-Founder & Chairman of Scientific Advisory Board
  • Mr. Eric H. Siegel J.D. (Age 59)
    MBA, General Counsel & Corporate Secretary
  • Ms. Terry Shields
    Senior Vice President of Human Resources
  • Mr. Tom Wilton (Age 50)
    Chief Business Officer
  • Dr. Eugene P. Kennedy F.A.C.S. (Age 55)
    M.D., Chief Medical Officer
  • Mr. Kenneth Locke
    Senior Vice President of Technical Operations

CARM Stock Analysis - Frequently Asked Questions

Should I buy or sell Carisma Therapeutics stock right now?

5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Carisma Therapeutics in the last twelve months. There are currently 5 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" CARM shares.
View CARM analyst ratings
or view top-rated stocks.

What is Carisma Therapeutics' stock price target for 2024?

5 Wall Street analysts have issued 1-year target prices for Carisma Therapeutics' stock. Their CARM share price targets range from $6.00 to $12.00. On average, they anticipate the company's share price to reach $8.60 in the next year. This suggests a possible upside of 537.0% from the stock's current price.
View analysts price targets for CARM
or view top-rated stocks among Wall Street analysts.

How have CARM shares performed in 2024?

Carisma Therapeutics' stock was trading at $2.93 on January 1st, 2024. Since then, CARM shares have decreased by 53.9% and is now trading at $1.35.
View the best growth stocks for 2024 here
.

When is Carisma Therapeutics' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, August 8th 2024.
View our CARM earnings forecast
.

How were Carisma Therapeutics' earnings last quarter?

Carisma Therapeutics, Inc. (NASDAQ:CARM) released its quarterly earnings results on Monday, April, 1st. The company reported ($0.52) earnings per share for the quarter. The business had revenue of $4.29 million for the quarter, compared to analysts' expectations of $4 million. Carisma Therapeutics had a negative net margin of 538.81% and a negative trailing twelve-month return on equity of 215.95%.

Who are Carisma Therapeutics' major shareholders?

Carisma Therapeutics' stock is owned by a number of retail and institutional investors. Top institutional investors include Vanguard Group Inc. (3.80%), Empowered Funds LLC (0.06%) and Concourse Financial Group Securities Inc. (0.00%).

How do I buy shares of Carisma Therapeutics?

Shares of CARM stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:CARM) was last updated on 5/26/2024 by MarketBeat.com Staff

From Our Partners